| 重度哮喘精准治疗的研究进展 |
| |
| 引用本文： | 杨宏宽. 重度哮喘精准治疗的研究进展[J]. 中国全科医学, 2020, 23(15): 1843-1848. DOI: 10.12114/j.issn.1007-9572.2019.00.662 |
| |
| 作者姓名： | 杨宏宽 |
| |
| 作者单位： | 525200广东省高州市人民医院呼吸与危重症医学科一区 |
| |
| 摘 要： | 重度哮喘患者急性发作频率高,具有较高的病死率,消耗着巨大的医疗卫生资源。目前以糖皮质激素为主的治疗方案对于重度哮喘患者效果有限且具有较大的不良反应,临床上亟须探索新的治疗方式。目前学术界认识到哮喘是一种异质性疾病,根据其病理机制可分为Th2型哮喘与非Th2型哮喘,通过一系列生物标志物的评估确定患者的内在型,进而选择合适的针对各靶点的单克隆抗体治疗,即精准治疗,在重度哮喘的治疗中展现出良好的应用前景。本文就哮喘的内在型分型及相对应的精准治疗做一系统阐述,旨在为重度哮喘的临床治疗提供参考。
|
| 关 键 词： | 哮喘 精准治疗 内在型 表型 抗体,单克隆, |
Advances in Research on Precision Therapy in Asthma Treatment |
| |
| YANG Hongkuan. Advances in Research on Precision Therapy in Asthma Treatment[J]. Chinese General Practice, 2020, 23(15): 1843-1848. DOI: 10.12114/j.issn.1007-9572.2019.00.662 |
| |
| Authors: | YANG Hongkuan |
| |
| Affiliation: | The First Section of Department of Respiration and Critical Care Medicine,Gaozhou People's Hospital,Gaozhou 525200,China
|
| |
| Abstract: | Patients with severe asthma have increased risk of exacerbations and morbidities with more healthcare costs.The glucocorticoid-based therapy in severe asthma is not satisfactory with several side effects.There is an agent need for a new therapy.Asthma is a disease with marked heterogeneity and can be divided into two endotypes depending on the pathological mechanism：T helper 2 Asthma and non-T helper 2 Asthma.Precision therapy is to identify a specific endotype through a complete evaluation of all available biomarkers and make a correct selection of monoclonal antibody targeted specific molecules,which has a promising outlook in the treatment of severe asthma.In this review,we discuss the endotypes and the related precision therapy in severe asthma in order to make a reference for the clinical practice. |
| |
| Keywords: | Asthma Precision therapy Endotypes Phenotypes Antibodies,monoclonal, |
|
| 点击此处可从《中国全科医学》浏览原始摘要信息 |
|
点击此处可从《中国全科医学》下载全文 |
|
